Filing Details

Accession Number:
0000899243-22-021250
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-06 19:00:13
Reporting Period:
2022-06-02
Accepted Time:
2022-06-06 19:00:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1680581 Fulcrum Therapeutics Inc. FULC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1577034 J Robert Gould C/O Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-06-02 16,689 $7.84 523,319 No 4 M Direct
Common Stock Disposition 2022-06-02 16,689 $7.92 506,630 No 4 S Direct
Common Stock Acquisiton 2022-06-03 25,551 $7.84 532,181 No 4 M Direct
Common Stock Disposition 2022-06-03 25,551 $7.95 506,630 No 4 S Direct
Common Stock Acquisiton 2022-06-06 24,382 $7.84 531,012 No 4 M Direct
Common Stock Disposition 2022-06-06 24,382 $8.10 506,630 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-06-02 16,689 $0.00 16,689 $7.84
Common Stock Stock Option (right to buy) Disposition 2022-06-03 25,551 $0.00 25,551 $7.84
Common Stock Stock Option (right to buy) Disposition 2022-06-06 24,382 $0.00 24,382 $7.84
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
207,891 2029-01-21 No 4 M Direct
182,340 2029-01-21 No 4 M Direct
157,958 2029-01-21 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.59, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
  5. This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the "2016 Plan") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022.